| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.023 | 0.9 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |